Galmed Pharmaceuticals
GLMD
16 hedge funds and large institutions have $5.39M invested in Galmed Pharmaceuticals in 2014 Q4 according to their latest regulatory filings, with 3 funds opening new positions, 7 increasing their positions, 1 reducing their positions, and 5 closing their positions.
600% more repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 1
16% less funds holding
Funds holding: 19 → 16 (-3)
40% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 5
46% less capital invested
Capital invested by funds: $10M → $5.39M (-$4.61M)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DCM
DAFNA Capital Management
Los Angeles,
California
|
+$248K |
| 2 |
Goldman Sachs
New York
|
+$202K |
| 3 |
6CM
683 Capital Management
New York
|
+$116K |
| 4 |
Morgan Stanley
New York
|
+$60.8K |
| 5 |
SIM
Spark Investment Management
New York
|
+$60.8K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VAM
Visium Asset Management
New York
|
-$1.33M |
| 2 |
Wells Fargo
San Francisco,
California
|
-$703K |
| 3 |
PRCM
Pine River Capital Management
Minnetonka,
Minnesota
|
-$680K |
| 4 |
EMG
Ellington Management Group
Old Greenwich,
Connecticut
|
-$96K |
| 5 |
BA
BlackRock Advisors
Wilmington,
Delaware
|
-$8K |
GLMD Hedge Fund Activity: Q4 2014 in Review
16 of the 3,750 institutional investors tracked by Wall St. Rank reported a position in Galmed Pharmaceuticals (GLMD) for Q4 2014, worth a combined $5.39M — down 46% from $10M a quarter earlier.
Sellers outnumbered buyers: 5 funds closed out of GLMD and 3 opened new positions — a net loss of 2 holders — while 1 trimmed existing stakes and 7 added.
The largest buyer was DAFNA Capital Management, adding an estimated $248K. The largest seller was Visium Asset Management, exiting entirely with an estimated $1.33M sold.
- 16 institutional investors held Galmed Pharmaceuticals (GLMD) as of Q4 2014, down from 19 in Q3 2014.
- Funds reported $5.39M of Galmed Pharmaceuticals stock for Q4 2014, down 46% quarter-over-quarter.
- 3 funds opened new Galmed Pharmaceuticals positions in Q4 2014 and 5 closed out, a net change of -2 holders.
- The largest Galmed Pharmaceuticals buyer in Q4 2014 was DAFNA Capital Management, an estimated $248K added.
- The largest Galmed Pharmaceuticals seller in Q4 2014 was Visium Asset Management, an estimated $1.33M sold.
Based on aggregated 13F filings for Q4 2014.